Communiqués Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Actions

TKD

JP3463000004

Marché Fermé - BOERSE MUENCHEN Autres places de cotation 20:44:00 14/06/2024			Varia. 5j.	Varia. 1 janv.
24,48 ^EUR	-0,16 %		-1,73 %	-5,45 %

14/06	Takeda signe un accord d'option avec Ascentage pour la licence d'un médicament contre la leucémie	MT
14/06	Takeda Pharmaceutical Company Limited signe un accord d'option avec Ascentage Pharma en vue de conclure une licence mondiale exclusive pour l'olverembatinib, un inhibiteur de tyrosine kinase BCR-ABL de troisième génération	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Takeda Signs Option Agreement with Ascentage Pharma to Enter into Exclusive Global License for Olverembatinib, a Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI)	14/06	BU
Takeda Announces Partnership Expansion with Partners In Health to Extend Community-Centered Health Equity Initiative Across Massachusetts	11/06	BU
Takeda Pharmaceutical : Notice Concerning Issuance of New Shares and Disposal of Treasury Shares under the Long Term Incentive Plan for Company Group Employees Outside of Japan Form 6 K	11/06	PU
TAKEDA PHARMACEUTICAL : Form 6 K	10/06	PU
Takeda Pharmaceutical : Statement from Masami Iijima, Chair of the Board of Directors Meeting of Takeda, in Response to Institutional Shareholder Services Inc.’s Voting Recommendations Ahead of the 148th Ordinary General Meeting of Shareholders Form 6 K	07/06	PU
Takeda Pharmaceutical - Notice Concerning Withdrawal of Shelf Registration Statement and Filing of New Shelf Registration Statement in Japan	04/06	AQ
Takeda’s TAK-861 Phase 2b Late-Breaking Data Presentations at SLEEP 2024 Demonstrate Clinically Meaningful Impact of Oral Orexin Agonist in Narcolepsy Type 1 Compared to Placebo	03/06	BU
Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 (rADAMTS13) in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)	31/05	BU
Takeda Pharmaceutical : Other items which are provided electronically	29/05	PU
TAKEDA PHARMACEUTICAL : Form 6-K	21/05	PU
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection	16/05	AQ
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting	14/05	BU
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease	13/05	BU
Takeda Announces Enterprise-wide Program to Support Growth and Deliver Core Operating Profit Margin Improvement	10/05	AQ
Takeda Pharmaceutical, Announces full-year 2023 results and outlook for 2024 Emphasizes commitment to late-stage pipeline development and core operating margin improvement	10/05	AQ
Takeda annonce ses résultats pour l’exercice 2023 et ses perspectives pour l’exercice 2024, confirmant son engagement en faveur du développement d’un portefeuille de produits à un stade avancé et de l’augmentation de la marge bénéficiaire...	10/05	BU
Takeda Pharmaceutical : FINANCIAL APPENDIX - Form 6-K	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Presentation	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Financial Report	09/05	PU
Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Highlights Infographic	09/05	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Actions

TKD

JP3463000004

Communiqués

Filtres